Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 241 clinical trials
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor 1-3

metastatic cancer
KIT
programmed cell death protein 1
advanced urothelial carcinoma
kinase inhibitor
  • 46 views
  • 26 Jan, 2021
  • 12 locations
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma

molecule multi-kinase inhibitor of VEGFR, PDGFR and RAF with demonstrated activity in the treatment of renal cell cancer (9). Preclinical studies suggest that the combination of Sorafenib with

platelet count
anthracyclines
dacarbazine
advanced soft tissue sarcoma
ifosfamide
  • 13 views
  • 07 Nov, 2020
  • 1 location
Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer ALTER-L029

Evaluate the efficacy and safety of Anlotinib following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer

  • 0 views
  • 23 Jan, 2021
  • 4 locations
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Currently the investigators have two different classes of second-line treatment options in recurrent non-small Cell Lung Cancer (NSCLC). In chemotherapy, docetaxel and pemetrexed produced similar treatment efficacy outcomes, while pemetrexed had a better tolerability. In recent analysis of pemetrexed clinical studies, a strong treatment-by-histology interaction in overall survival and progression …

pemetrexed
cancer chemotherapy
measurable disease
alimta
tyrosine
  • 9 views
  • 07 Nov, 2020
  • 1 location
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

The aim of this study is to demonstrate that the use of Gleevec in initially non-resectable gastrointestinal stromal tumors can lead to allow complete resection in 20% of cases.

imatinib
partial resection
gleevec
complete resection
measurable disease
  • 6 views
  • 07 Nov, 2020
  • 1 location
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell mediator release, unresponsive to optimal symptomatic treatment.

  • 0 views
  • 26 Jan, 2021
  • 7 locations
Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy

The primary objective of this study is to evaluate the tolerability and the maximum tolerated dose of Conformal or Intensity-Modulated Radiotherapy when given in combination with gefitinib 250mg in Chinese patients with IIIB or IV NSCLC after failure of platinum-based chemotherapy. Secondary objectives of the study are to obtain the …

gefitinib
platinum-based chemotherapy
cancer chemotherapy
pleural effusion
metastasis
  • 1 views
  • 07 Nov, 2020
  • 1 location
TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

In this phase II trial with single arm, we aim to investigate the clinical efficacy and toxicity profile of local radiotherapy on all disease sites for EGFR-mutant oligo-metastatic NSCLC (no more than 3 metastatic lesions) who did not experience disease progression after at least 3 months of TKI therapy.

EGFR
  • 0 views
  • 23 Jan, 2021
  • 1 location
Treatment Modification Based on Early Assessment of CML Patients

The investigators will check the feasibility of using early molecular response for making treatment decisions. Patients diagnosed with chronic myeloid leukemia will commence imatinib treatment. After 3 months of treatment their response will be assessed. If molecular response would be less the 10% (BCR-ABL1/ABL ISI >10%)imatinib therapy will be stopped …

leukemia
tyrosine
imatinib
kinase inhibitor
nilotinib
  • 5 views
  • 08 Nov, 2020
  • 1 location
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

This study aims to test if patients achieving a tumor response with the combination of axitinib plus avelumab, can discontinued the axitinib in order to delay the resistance to the anti VEGFR-TKI and decrease the related toxicity of the combination therapy.

  • 0 views
  • 27 Jan, 2021
  • 20 locations